SCHEMBL373408

SCHEMBL373408

CCCCCCCCCCCCCCCCCC(=O)O[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
MAPK1 P28482 1/20 0.54
LMNA P02545 4/20 0.49
PRKCA P17252 5/20 0.48
PRKCE Q02156 2/20 0.48
PRKCQ Q04759 2/20 0.48
PRKCD Q05655 2/20 0.48
KDM4E B2RXH2 1/20 0.47
DUSP3 P51452 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 2/20 0.44
DGKA P23743 1/20 0.44
FAAH O00519 1/20 0.42
HPGD P15428 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8502959 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL769533 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL2800456 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL8190440 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL15262436 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL19458643 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL15463455 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL11801281 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL6357113 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE
SCHEMBL10763839 1.00 MAPT (0.54) MAPTMAPK1LMNAPRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113181073-B Composite vitamin emulsion, wrinkle-removing essence cream and preparation method thereof 广州市科能化妆品科研有限公司 2022-12-23 CN claimed
CN-111437214-B Retinol inclusion, anti-aging and wrinkle-removing essence and preparation method thereof 广州市科能化妆品科研有限公司 2022-05-13 CN claimed
CN-113181073-A Composite vitamin emulsion, wrinkle-removing essence cream and preparation method thereof 广州市科能化妆品科研有限公司 2021-07-30 CN claimed
US-20200236933-A1 USE OF A NON-IONIC SURFACTANT WHICH IS A POLYOL DERIVATIVE AS A PLANT GROWTH STIMULATING AGENT OR AS AN ADJUVANT INNOVI (FR) 2020-07-30 US claimed
CN-111437214-A Retinol inclusion, anti-aging and wrinkle-removing essence and preparation method thereof 广州市科能化妆品科研有限公司 2020-07-24 CN claimed
CN-111432640-A Use of nonionic surfactants of polyol derivatives as plant growth stimulators or as adjuvants 宜诺维 2020-07-17 CN claimed
EP-3664610-A2 USE OF A NON-IONIC SURFACTANT WHICH IS A POLYOL DERIVATIVE AS A PLANT GROWTH STIMULATING AGENT OR AS AN ADJUVANT INNOVI (FR) 2020-06-17 EP claimed
US-20180200180-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY WM. WRIGLEY JR. COMPANY 2018-07-19 US claimed
EP-3322487-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY WM. Wrigley Jr. Company (US) 2018-05-23 EP claimed
WO-2017011665-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY WM. WRIGLEY JR. COMPANY (US) 2017-01-19 WO claimed
US-12521342-B2 Fast disintegrating tablet CUBOPHARM PTY LTD (AU) 2026-01-13 US disclosed
US-12521350-B2 Liquid crystalline dosage form for administering a statin CUBOPHARM PTY LTD (AU) 2026-01-13 US disclosed
US-12441934-B2 Viscosifying friction reducers Energy Solutions (US) LLC (US) 2025-10-14 US disclosed
US-12428593-B2 Hydraulic fracturing fluids and methods of use with friction reducer slurry formulation INDEPENDENCE OILFIELD CHEMICALS LLC (US) 2025-09-30 US disclosed
WO-2025102064-A1 FRICTION REDUCER POLYMERS FOR OILFIELD APPLICATIONS Energy Solutions (US) LLC (US) 2025-05-15 WO disclosed
US-5739190-A Process for the preparation of stable water-in-oil emulsions of hydrolyzed polymers of N-vinyl amides and the use thereof BASF AKTIENGESELLSCHAFT (DE) 1998-04-14 US disclosed
WO-1994012651-A1 ENZYMATIC SYNTHESIS OF SUGAR ALCOHOL ESTERS NOVO NORDISK A/S (DK) 1994-06-09 WO disclosed
US-5292800-A Epichlorohydrin, alcohol, polyol, alkoxylation BASF AKTIENGESELLSCHAFT (DE) 1994-03-08 US disclosed
US-5162116-A Intra-ruminal device for delivering drugs COOPERS ANIMAL HEALTH LIMITED (GB) 1992-11-10 US disclosed
EP-0373890-A1 Intra-ruminal device COOPERS ANIMAL HEALTH LIMITED (GB) 1990-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180200180-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY MLEC, CD14, HIRA MAPT 3493/4885MAPK1 3997/4885LMNA 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.